Page 4 - HFA Dateline 2022 Special Edition

IN THIS ISSUE

DEPARTMENTS
Assisting, educating, and advocating
for the bleeding disorders
5
Executive Corner community since 1994.
Volume 22 • Issue 2 • Special Issue 2022

6 a Form Board Chair • Allie Ritcey
Informed Consent: A Process, Not Just EXECUTIVE LEADERSHIP

PRODUCTION TEAM
Editor • Meghan Lawton
Managing Editor • Melanie
8 Design & Layout • Brad Latham
A Look at the Drug Recall Process Padgett Powers

Contributing Writers
12 Jennifer Larson
Weighing the Benefits of Gene Therapy Dara Chadwick

The information printed in
Dateline Federation is provided
20 Is Factor Still Relevant? for general purpose use. HFA does

not give medical advice or engage
in the practice of medicine and
recommends that you consult with your
44 FDA Drug Approval Process physician or local treatment center before

beginning any form of treatment.

Requests for permission to translate
76 Clinical Studies: How Do They Work? or reprint contents of Dateline

Federation should be directed to
info@hemophiliafed.org.

999 N. Capitol Street NE • Suite 301
Washington, DC 20002
202.675.6984
FEATURED SECTIONS info@hemophiliafed.org

©2022 Hemophilia Federation of America.
26 Current Products for Treatment All rights reserved.

Connect with us on social media
for daily posts and updates
about what’s happening at HFA.
48 Emerging Therapies

DATELINE FEDERATION < www.hemophiliafed.org
4 4 DATELINE FEDERATION < www.hemophiliafed.org